Clinical library | PharmD Signal

KRAS Inhibitors May Unlock Immunotherapy in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

Stanger BZ, Vonderheide RH

Apr 15, 2026 · Published in: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

KRAS inhibitors may revolutionize immunotherapy for pancreatic cancer.

Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
Analysis Oncology Pharmacy Practice-changing Grade: High

Sinicrope FA, Ou FS, Arnold D, et al.

Mar 26, 2026 · Published in: N Engl J Med

Atezolizumab enhances survival in dMMR colon cancer.

Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation
Analysis Oncology Pharmacy Confirmatory Grade: Very Low

Kong Y, He R, He H, et al.

Feb 25, 2026 · Published in: Rev Cardiovasc Med

New biomarkers offer promise for early detection of chemotherapy-induced heart damage.

KRAS Inhibitors Reshape the Treatment Landscape in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Khan N, Raza U, Ali Zaidi SA, et al.

Jul 7, 2025 · Published in: Cancer Biology & Medicine

KRAS: From 'undruggable' to potential target in pancreatic cancer.

Adagrasib Shows Tumor-Agnostic Activity in Rare KRAS G12C Solid Tumors
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Bekaii-Saab TS, Yaeger R, Spira AI, et al.

Sep 1, 2023 · Published in: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Adagrasib shows promise in rare KRASG12C-mutated tumors.

Sotorasib Shows Modest Activity in KRAS G12C Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Strickler JH, Satake H, George TJ, et al.

Jan 5, 2023 · Published in: The New England Journal of Medicine

Sotorasib offers hope for KRAS p.G12C-mutated pancreatic cancer.

Clinical Specialty Index